Clinical Trials Logo

Clinical Trial Summary

Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate. Four randomized, double-blind trials have been carried out in patients with postmenopausal osteoporosis. In 2 of these studies, vertebral fracture incidence was reduced by a daily dose of 5 mg risedronate by up to 65% and 49% relative to placebo after 1 and 3 years, respectively. In these trials, risedronate improved lumbar spine, femoral neck, and femoral trochanter bone mineral density (BMD) at 6 months. In addition, preclinical studies have shown that risedronate is more potent than pamidronate and clodronate in inhibiting adhesion of prostate cancer cells to bone and preventing tumor cell invasion. The incidence of osteoporosis in prostate cancer patients has been well established; therefore, it is advantageous to assess the efficacy of oral bisphosphonate therapy.


Clinical Trial Description

OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter, 2 arm study.

The study population will consist of prostate cancer patients with metastatic bone disease for whom androgen-deprivation therapy is planned. After stratification based on the patient's age, performance status, and severity of metastatic disease, the patients will be randomized at a 1:1 ratio to the following treatment arms:

- Daily oral risedronate combined with androgen deprivation

- Daily oral placebo combined with androgen deprivation

Initial clinical evaluation will be performed during the 2-week screening period. While patients receive per-protocol treatment, study assessments will be performed every 4 weeks during the first 3 months, and every 12 weeks thereafter.

Performance Status: Eastern Cooperative Oncology Group (ECOG) 0 to 2

Life Expectancy: At least 12 weeks

Hematopoietic:

- Absolute neutrophil count (ANC) > 1,000/mm3

- Platelet count > 100,000/mm3

- international normalized ratio (INR) < 1.5 x upper limit of normal unless on therapeutic anticoagulation

- Partial thromboplastin time (PTT) < 1.5 x upper limit of normal unless on therapeutic anticoagulation

Hepatic:

- Bilirubin < 1.5 mg/dL

- Alanine transaminase (ALT) < 2.5 x upper limit of normal

Renal:

- Creatinine clearance of > 30 mL/min (by Cockcroft-Gault)

Cardiovascular:

- No significant history of uncontrolled cardiac disease (i.e., uncontrolled hypertension, unstable angina, and congestive heart failure).

Pulmonary:

- Not specified

Calcium:

- Corrected serum calcium = (4.0 g/dL - actual albumin g/dL)x 0.8 + serum calcium ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00216060
Study type Interventional
Source Hoosier Cancer Research Network
Contact
Status Terminated
Phase Phase 3
Start date October 2003
Completion date March 2008

See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Recruiting NCT04533958 - Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy N/A
Not yet recruiting NCT06009549 - A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
Withdrawn NCT05771896 - Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC Phase 3
Completed NCT01981122 - A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Phase 2
Completed NCT01233557 - Biomarkers of Bone Resorption in Metastatic Prostate Cancer N/A
Completed NCT01012141 - Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer Phase 2
Recruiting NCT04067713 - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
Active, not recruiting NCT04332744 - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) Phase 2
Completed NCT04545697 - mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer N/A
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Completed NCT02278055 - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT06112990 - Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression Phase 3
Completed NCT04193657 - Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Completed NCT02260817 - Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer Phase 3
Recruiting NCT04070209 - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Phase 2
Recruiting NCT04925648 - Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction Phase 2
Completed NCT01303705 - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Phase 1